Recent clinical evidence underscores the role of Chlamydia trachomatis infection as a critical co-factor in the development of cervical epithelial cell abnormalities. While the oncogenic human papilloma virus (HPV) remains the primary cause of cervical cancer, secondary infections often exacerbate the progression of these lesions. Consequently, a recent study evaluated the seroprevalence of Chlamydia antibodies among women with normal and abnormal Papanicolaou (Pap) smear results to determine its clinical impact.

The researchers conducted a hospital-based cross-sectional comparative study involving 100 participants. Specifically, they compared 50 women with abnormal Pap smears (cases) against 50 women with normal results (controls). Furthermore, the team utilized anti-Chlamydia trachomatis antibody tests to measure seroprevalence in both groups. The results revealed a significant disparity, as 20% of the cases tested positive compared to only 2% of the controls. Thus, the data indicates a strong association between the presence of these antibodies and cervical cell atypia.

Clinical Implications of Chlamydia trachomatis infection in Screening

The statistical analysis further highlighted the risk associated with this bacterium. According to the binary logistic regression, Chlamydia trachomatis infection increased the odds of abnormal cervical cytology by nearly 13 times. Moreover, the study found that women with more than three lifetime sexual partners faced a significantly higher risk of infection. Therefore, clinicians should consider these findings when interpreting abnormal Pap smears in sexually active women. Because Chlamydia causes chronic inflammation, it potentially facilitates the persistence of HPV, thereby accelerating oncogenic transformation. Additionally, integrating Chlamydia screening into existing cervical cancer protocols could identify high-risk individuals more effectively.

Frequently Asked Questions

How does Chlamydia trachomatis infection contribute to cervical cancer?

While Chlamydia does not cause cancer directly, it induces chronic inflammation and mucosal damage. Consequently, this environment allows high-risk HPV strains to persist and integrate into the host genome more easily, leading to malignancy.

Should clinicians recommend Chlamydia testing for women with abnormal Pap smears?

Yes, medical guidelines often suggest testing for Chlamydia trachomatis infection in women with abnormal cytology. Since doctors can easily treat the infection, early intervention helps reduce local inflammation and mitigates the risk of further epithelial damage.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.

References

Ifezuoke TD et al. Chlamydia trachomatis infection seroprevalence among women with normal and abnormal cervical smears and its implication for Nigerian cervical cancer screening. BMC Infect Dis. 2026 Mar 04. doi: 10.1186/s12879-026-12994-4. PMID: 41782106.

Pillai VN et al. Prevalence of human papilloma virus and Chlamydia trachomatis in endometrial and cervical carcinoma: a comparative study in North Indian women. J Obstet Gynaecol. 2023;43(1):2247517. doi: 10.1080/01443615.2023.2247517. PMID: 37668557.

World Health Organization. Comprehensive cervical cancer control: a guide to essential practice. Second edition. 2014.